中度大分割同步整合推量调强放疗联合替莫唑胺治疗胶质母细胞瘤术后疗效
单中心回顾性分析80例新诊断胶质母细胞瘤术后患者,接受中度大分割同步整合推量调强放疗(SIB-IMRT)联合替莫唑胺(TMZ)治疗。中位随访16个月,中位无进展生存期15个月,中位总生存期21个月,毒性轻微可接受。年龄、KPS评分和TMZ总周期数是影响生存的显著因素。
要点
- 中度大分割SIB-IMRT联合TMZ治疗GBM术后可行安全,毒性轻微。
- 中位PFS 15个月,中位OS 21个月,3年OS率32.8%。
- 年龄、KPS评分和TMZ总周期数是显著预后因素。
核心结论
- 中度大分割SIB-IMRT联合TMZ是毒性轻微、PFS和OS良好的可行安全治疗选择。
研究设计与样本
- 单中心回顾性研究,纳入2012年2月至2018年2月80例新诊断且组织学确诊的GBM术后患者。
- 所有患者接受完全或部分切除术后行大分割SIB-IMRT联合同期TMZ,后续辅助TMZ。
- 放疗剂量:GTV 64 Gy/27次,CTV1 60 Gy/27次,CTV2 54 Gy/27次。
主要发现
- 中位随访16个月(范围5~72个月)。
- 中位PFS 15个月,1年、2年、3年PFS率分别为56.0%、27.6%、19.5%。
- 中位OS 21个月,1年、2年、3年、5年OS率分别为77.6%、41.6%、32.8%、13.4%。
- 毒性轻微且可接受。
- 年龄、KPS评分和TMZ总周期数是影响患者生存的显著因素。
关键数值与推荐
- GTV总剂量64 Gy分27次,CTV1 60 Gy分27次,CTV2 54 Gy分27次。
临床怎么用
- 对于新诊断GBM术后患者,可考虑中度大分割SIB-IMRT联合TMZ方案。
- 治疗中关注年龄、KPS评分和TMZ周期数等预后因素。
局限性
- 单中心回顾性研究,样本量80例,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Despite recent advances in multimodal treatments, the prognosis of patients with glioblastoma multiforme (GBM) remains poor. The aim of this study was to evaluate the efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with temozolomide (TMZ) for the postoperative treatment of GBM. MATERIALS AND METHODS: From February 2012 to February 2018, 80 patients with newly diagnosed and histologically confirmed GBM in our institute were reviewed retrospectively. All patients underwent complete resection or partial resection surgery and then received hypofractionated SIB-IMRT with concomitant TMZ followed by adjuvant TMZ. A total dose of 64 Gy over 27 fractions was delivered to the gross tumor volume (GTV), clinical target volume 1 (CTV1) received 60 Gy over 27 fractions, and CTV2 received 54 Gy over 27 fractions. The progression-free survival (PFS) and overall survival (OS) rates and the toxicities were evaluated. Prognostic factors were analyzed using univariate and multivariate Cox models. RESULTS: The median follow-up was 16 months (range, 5~72 months). The median PFS was 15 months, and the 1-, 2-, and 3-year PFS rates were 56.0, 27.6, and 19.5%, respectively. The median OS was 21 months, and the 1-, 2-, 3-, and 5-year OS rates were 77.6, 41.6, 32.8, and 13.4%, respectively. The toxicities were mild and acceptable. Age, KPS scores and the total number of TMZ cycles were significant factors influencing patient survival. CONCLUSION: Moderately hypofractionated SIB-IMRT combined with TMZ is a feasible and safe treatment option with mild toxicity and good PFS and OS.
引用
- Zhong L, Chen L, Lv S, et al. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience. Radiat Oncol. 2019. PMID: 31196126. doi:10.1186/s13014-019-1305-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。